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review of randomized
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Gabor S. Ungvari6,7, Chee H. Ng8,
Andrei Golenkov9, Grace K.I. Lok5, Lu Li5,
Ines H.I. Chow5, Fei Wang5 and Yu-Tao Xiang5
Abstract
This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct
for antipsychotic-induced weight gain in patients with schizophrenia. RCTs reporting weight gain
or metabolic side effects in patients with schizophrenia were included. Case reports/series, non-
randomized or observational studies, reviews, and meta-analyses were excluded. The primary
outcome measures were body mass index (BMI) (kg/m2) and body weight (kg). Four RCTs with five
study arms were identified and analyzed. Compared with the control group, adjunctive ranitidine
was associated with marginally significant reductions in BMI and body weight. After removing an
outlier study for BMI, the effect of ranitidine remained significant. Adjunctive ranitidine
outperformed the placebo in the negative symptom score of the Positive and Negative
Syndrome Scale. Although ranitidine was associated with less frequent drowsiness, other adverse
events were similar between the two groups. Adjunctive ranitidine appears to be an effective and
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safe option for reducing antipsychotic-induced weight gain and improving negative symptoms in
patients with schizophrenia. Larger RCTs are warranted to confirm these findings.
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Introduction
Antipsychotic (AP)-induced weight gain is
common in patients with schizophrenia and
has received increased attention in recent
decades.1–7 In one study, up to 75% of
patients with a ﬁrst episode of schizophrenia
receiving APs experienced weight gain of
7%.8 AP-induced weight gain not only
increases the risk of diabetes mellitus, car-
diovascular disease, and mortality but also
contributes to poor treatment adherence
and low quality of life.2,3,9–11
Histamine H2 receptors play an import-
ant role in the mechanism of AP-induced
weight gain, together with the serotonergic,
noradrenergic, and histaminergic systems.12
Ranitidine, a non-imidazole H2 blocker, is
an inexpensive medication with a low risk of
adverse eﬀects because of its negligible
eﬀects on muscarinic, nicotinic, adrenergic,
and H1 receptors.13 Although several ran-
domized controlled trials (RCTs)13–16 have
examined the eﬃcacy and safety of adjunct-
ive ranitidine for AP-induced weight gain in
patients with schizophrenia, the results were
mixed.
To the best of our knowledge, no system-
atic reviews or meta-analyses on ranitidine
as an adjunctive treatment for AP-induced
weight gain in patients with schizophrenia
have been published. Therefore, we per-
formed the present meta-analysis of
RCTs of adjunctive ranitidine for all AP-
induced weight gain in patients with schizo-
phrenia. We also included recent RCTs
published in Chinese-language journals
that may not be widely known on an
international basis.
Methods
Search strategy and selection criteria
Two reviewers independently and system-
atically searched the PubMed, PsycINFO,
Embase, Cochrane Library, Chinese
Journal Net, WanFang, and China Biology
Medicine databases for articles regarding
adjunctive ranitidine for schizophrenia from
inception of each database until 10 October
2016. The keywords used for the search were
(zantic OR ranitidine OR zantic OR Zantac)
AND (schizophrenic disorder OR disorder,
schizophrenic OR schizophrenic disorders
OR schizophrenia OR dementia praecox).
We also hand-searched reference lists from
relevant review articles for additional studies
and contacted the authors for more infor-
mation if necessary.
The following criteria were used accord-
ing to the PICOS acronym. Participants
(P): adult patients (18 years of age)
with schizophrenia using any diagnostic
criteria. Intervention (I): ranitidine plus
APs. Comparison (C): APs plus placebo or
AP monotherapy. Outcomes (O): eﬃcacy
and safety. Study design (S): RCT report-
ing body weight or metabolic adversities as
primary or secondary outcomes. Case
reports/series, non-randomized or observa-
tional studies, reviews, and meta-analyses
were excluded.
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Outcome measures
The primary outcome measures were body
mass index (BMI) (kg/m2) and body weight
(kg). Key secondary outcomes were clinical
improvement assessed by the Positive and
Negative Syndrome Scale (PANSS)17 or the
Brief Psychiatric Rating Scale,18 discontinu-
ation rate, and adverse drug reactions
(ADRs).
Data extraction
Data were identiﬁed, checked, extracted,
and analyzed by two independent reviewers.
Furthermore, outcomes based on intention-
to-treat analysis, if available, were recorded.
Any inconsistencies were discussed with and
resolved by a third reviewer.
Statistical methods
According to the guidelines of the Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement,19
Review Manager (RevMan) Version 5.3
(http://tech.cochrane.org/revman/) was used
to perform the meta-analysis. For meta-
analytic pooling of continuous and dichot-
omous outcomes, the inverse variance
method and Mantel–Haenszel test were
used to present weighted mean diﬀerences
(WMDs) and risk ratios (RRs) with their
95% conﬁdence intervals (CIs), respectively.
When the RR was signiﬁcant, the number
needed to treat or number needed to harm
(NNH) was calculated by dividing 1 by the
risk diﬀerence. Each missing standard devi-
ation (SD) was replaced by the average
SD from other RCTs that used the same
medication.20 To compensate for study het-
erogeneity, a random-eﬀects model was used
in all meta-analyzable data.21 Both I2 and
chi-square statistics were used to identify
heterogeneity. When heterogeneity (chi-
squared P< 0.1 and I2> 50%) was present
for BMI, a sensitivity analysis was con-
ducted to examine the credibility of the BMI
change by excluding one study16 with an
outlying eﬀect size (ES) of less than 1.5 (i.e.
more than 1.5 SD superiority of ranitidine).
In addition, one subgroup analysis was per-
formed (Chinese versus non-Chinese
patients). One study13 with three treatment
arms compared the combination of ranitidine
and two diﬀerent doses of APs with a control
group. Half of the patients were assigned to
each ranitidine arm to avoid inﬂating the
number of patients in the control group.
Publication bias was assessed using funnel
plots and Egger’s test.22 All analyses were
two-tailed, with alpha set at 0.05.
Assessment of reporting biases
According to the recommendations of the
Cochrane Collaboration, the Cochrane risk
of bias was used to assess the methodo-
logical quality of RCTs (Supplementary
Figure 1). Their domain was rated as ‘‘high
risk,’’ ‘‘unclear risk,’’ or ‘‘low risk.’’23
The Grading of Recommendations
Assessment, Development and Evaluation
(GRADE) system was used to rate each
study as ‘‘very low,’’ ‘‘low,’’ ‘‘moderate,’’
or ‘‘high’’ with respect to the quality of
evidence of adjunctive ranitidine versus pla-
cebo. Furthermore, the Jadad scale (Table 1)
ranging from 0 to 5 was used to judge the
quality of each RCT.24
Results
Results of the search
Figure 1 presents a ﬂow chart of article
selection from the English (n¼ 114) and
Chinese databases (n¼ 11). The full text of
one RCT25 published in Spanish could not
be obtained. In total, four RCTs13–16 were
eligible and included in this meta-analysis.
Study characteristics
The four RCTs13–16 with ﬁve study arms
(n¼ 315) comprised three double-blinded
24 Journal of International Medical Research 46(1)
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trials (n¼ 240) and one open label study
(n¼ 75) comparing an adjunctive ranitidine
group (n¼ 170) and a control group
(n¼ 145). The weighted mean treatment
duration was 15.8 weeks (range¼ 8–24
weeks) (Table 1). Two RCTs were con-
ducted in China (n¼ 188), one was con-
ducted in India (n¼ 75), and one was
conducted in Iran (n¼ 52).
Patient characteristics
The weighted mean age was 32.4 years
(range¼ 28.6–38.1 years), the mean percentage
of male patients was 64% (range¼ 52.5%–
89.3%), and the weighted mean illness dur-
ation (according to the available data in two
RCTs13,15) was 3.2 years (range¼ 1.6–5.0
years) (Table 1). All RCTs were conducted
in inpatient settings.
Treatment characteristics
The weighted mean dosage of ranitidine was
339.5mg/day (range¼ 150–600mg/day). All
included studies involved only patients who
received olanzapine. The weighted mean
dosage of olanzapine was 19.1mg/day
Records identified through database 
search (n = 125) 
Additional records identified 
through other sources (n = 0) 
Records after duplicates removed (n = 81) 
Records screened (n = 81) Records excluded based on title and 
abstract (n = 74) 
Full-text articles assessed 
for eligibility (n = 7) 
Full-text articles excluded (n = 3): 
-Reviews (n = 2) 
-Failure to obtain full text (n = 1) 
Studies included in 
qualitative synthesis (n = 4) 
Studies included in 
quantitative synthesis 
(meta-analysis) (n = 4 RCTs 
with 5 study arms) 
Figure 1. PRISMA flow diagram. RCT, randomized controlled trial.
26 Journal of International Medical Research 46(1)
(range¼ 5–30mg/day) according to the
available data in three RCTs.13,15,16
Quality assessment
All four RCTs mentioned ‘‘randomized
allocation’’ with a speciﬁc description,
while the allocation concealment method
was rated as ‘‘unclear’’ in one RCT and
‘‘high risk’’ in another RCT. Three RCTs
were double-blinded trials, and one RCT
was an open label study. Regarding incom-
plete outcome data, one RCT reported loss
to follow-up but failed to use intention-to-
treat analysis. Furthermore, two RCTs
employed a protocol registration and were
rated as ‘‘low risk’’ regarding selective report-
ing (Supplementary Figure 1). The quality of
evidence presented for the primary and sec-
ondary outcomes using the GRADE
approach ranged from ‘‘low’’ (86%) to
‘‘moderate’’ (14%) (Table 2).
The weighted mean total Jadad score of
the four RCTs was 3.9 (range¼ 3–5), and all
studies were rated as high-quality (Jaded
score of 3) (Table 1).
Primary outcomes
Compared with the control group, raniti-
dine was associated with a marginally sig-
niﬁcant decrease in the BMI (4 RCTs with 5
study arms, n¼ 312; WMD: 1.08 kg/m2;
95%CI: 2.15, 0.01; P¼ 0.05; I2¼ 94%)
(Figure 2). However, the BMI change
was signiﬁcant even after removing an out-
lier study16 (n¼ 120; ES<1.5; WMD:
0.58 kg/m2; 95%CI: 1.08, 0.07;
P¼ 0.02; I2¼ 64%). Moreover, the sub-
group analysis revealed that statistical
signiﬁcance was lost for studies of both
non-Chinese patients (2 RCTs with 3 study
arms, n¼ 127) and Chinese patients (2 RCTs,
n¼ 185). Furthermore, patients taking
Table 2. GRADE analyses: Adjunctive ranitidine for antipsychotic-induced weight gain.
Design
N
(arms)
Risk of
bias Inconsistency Indirectness Imprecision
Publication
bias
Large
effect
Overall quality
of evidencea
Body weight (kg) 312 (5) None Seriousb None None Seriousc None þ/þ///; Low
BMI (kg/m2) 260 (4) None Seriousb None None Seriousc None þ/þ///; Low
PANSS total score 75 (2) Seriousd None None None Seriousc None þ/þ///; Low
PANSS positive
symptom score
75 (2) Seriousd None None None Seriousc None þ/þ///; Low
PANSS negative
symptom score
75 (2) Seriousd None None None Seriousc None þ/þ///; Low
PANSS general
symptom score
75 (2) Seriousd None None None Seriousc None þ/þ///; Low
Drowsiness 165 (3) None None None None Seriouse None þ/þ/þ//;
Moderate
BMI¼ body mass index; GRADE¼Grading of Recommendations Assessment, Development and Evaluation;
PANSS¼ Positive and Negative Syndrome Scale.
aGRADE Working Group grades of evidence: High quality¼ further research is very unlikely to change our confidence in
the estimate of effect. Moderate quality¼ further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate. Low quality¼ further research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to change the estimate. Very low quality¼we are very uncertain about
the estimate.
bAll studies that reported having a serious inconsistency had I2> 50%.
cFor continuous outcomes, N< 400.
dAll studies that reported having a serious bias used a open label method and only mentioned random allocation without
describing the method.
eFor dichotomous outcomes, N< 300.
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ranitidine did not lose weight to a statistically
signiﬁcant degree but only showed a trend
(3 RCTs with 4 study arms, n¼ 260; WMD:
1.54kg; 95%CI: 3.13, 0.04; I2¼ 78%)
(Figure 2) compared with the control
group. Because only four RCTs with ﬁve
study arms were included for assessment of
the primary outcomes, the presence of pub-
lication bias regarding weight change and
BMI could not be determined by performing
a funnel plot or Egger’s test (<10 trials).26
Secondary outcomes
With respect to clinical outcomes, only one
RCT with two study arms used the PANSS.
The adjunctive ranitidine group outper-
formed the control group in terms of
PANSS negative symptom scores (1 RCT,
n¼ 75; WMD: 1.95; 95%CI: 3.62,
0.28; P¼ 0.02; I2¼ 0%) (Figure 3), but
not in terms of PANSS total, positive, or
general symptom scores (1 RCT, n¼ 75;
WMD: 0.44 to 0.77; 95%CI: 3.88, 2.99;
I2¼ 0%) (Figure 3).
In terms of ADRs, adjunctive ranitidine
was associated with less frequent drowsiness
than in the control group (3 RCTs, n¼ 165;
RR: 0.55; 95%CI: 0.35, 0.86; P¼ 0.008;
I2¼ 0%; NNH¼ 6; 95%CI¼ 3, 100)
(Figure 4). Meta-analyses of akathisia, rigid-
ity, tremor, dry mouth, headache, and
constipation showed no signiﬁcant group
diﬀerences (Figure 4).
One RCT15 reported a discontinuation
rate of 6% (2/35) in the ranitidine group
versus 3% (1/33) in the control group. The
remaining RCTs did not report the discon-
tinuation rate.
Discussion
To the best of our knowledge, this is the ﬁrst
meta-analysis to examine the eﬀect of
adjunctive ranitidine on AP-induced weight
gain. The adjunctive ranitidine group outper-
formed the control group in terms of reduc-
tions in weight gain and improvements in
negative symptoms. Furthermore, ranitidine
was well tolerated. These positive eﬀects of
ranitidine support the hypothesis that the
histamine H2 receptor is a possible mediator
of eating behavior and weight regulation.27
Importantly, the signiﬁcance the eﬀect
remained when the one outlier (ES<1.5)16
was excluded from the analysis. The lack of
Figure 2. Ranitidine for antipsychotic-induced weight gain: Forest plot for changes in body weight and body
mass index.
BMI, body mass index; SD, standard deviation; IV, interval variance; CI, confidence interval.
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signiﬁcant results regarding Chinese and non-
Chinese participants in the subgroup analysis
could have been due to the small sample size,
which reduced the power to detect statistically
signiﬁcant results.
In this study, the ranitidine group was
superior to the control group with respect to
improvements in negative symptoms
(WMD¼1.95). This may have been due
to the direct drug receptor activity of raniti-
dine itself.13 Ranitidine has been shown to
be relatively safe and well tolerated in
patients with schizophrenia. Drowsiness
(NNH¼ 6) was less frequent in the raniti-
dine group than in the control group, and no
group diﬀerence in other ADRs was evident.
Topiramate and metformin may also
improve AP-related metabolic ADRs.6
However, we could not locate any head-to-
head trials comparing adjunctive ranitidine
with topiramate/metformin in patients with
schizophrenia.
Limitations
This study had several limitations. First,
there was signiﬁcant heterogeneity of the
results in terms of the primary outcomes.
However, a random-eﬀects model was
employed to provide a conservative estimate
for all meta-analyzable outcomes. Second,
only a few studies were available for the
meta-analysis because the use of ranitidine
for weight loss is oﬀ-label. The inclusion of
only 4 RCTs involving 315 patients and the
limited or incomplete information lessen
the conﬁdence of the results and limit more
comprehensive data exploration, such as
meta-regression analyses. Third, although
all four RCTs were rated as high-quality
using the Jadad scale,24 86% were rated
as ‘‘low’’ using the GRADE approach,
especially for BMI and weight change.
Furthermore, publication bias for primary
outcomes could not be examined because of
Figure 3. Ranitidine for antipsychotic-induced weight gain: Forest plot for clinical efficacy assessed by
changes in the Positive and Negative Syndrome Scale (PANSS) score.
SD, standard deviation; IV, interval variance; CI, confidence interval.
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the limited number of studies.28 Fourth,
because the ranitidine dosages varied from
150 to 600mg/day, the dose–response eﬀect
of ranitidine in weight loss could not be
further evaluated. Fifth, all RCTs used
olanzapine as the baseline AP; therefore,
the results could not be generalized to other
APs. Furthermore, the >24-week long-term
eﬀects of adjunctive ranitidine on body
weight could not be investigated. Finally,
Figure 4. Ranitidine for antipsychotic-induced weight gain: Forest plot for adverse drug reactions. MH,
Mantel–Haenszel.
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other metabolic indices including the lipid
proﬁle, insulin resistance, and leptin con-
centration were not recorded in the included
studies.
Conclusions
Adjunctive ranitidine appears to be an
eﬀective and safe option for treating weight
gain and negative symptoms in patients with
schizophrenia. Because of the small number
of studies available for this meta-analysis,
the results should be regarded as prelimin-
ary. The long-term eﬀects of ranitidine on
weight change and negative symptoms need
to be examined in further studies with
improved methodology. In addition, the
eﬀect of ranitidine on weight gain in patients
with other psychiatric disorders should be
examined in systematic reviews.
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